MetaCap

HeartSciences (HSCS) vs CollPlant Biotechnologies (OPHI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

HeartSciences is the larger company by market cap ($10.4 million vs $9.6 million), about 1.1 times the size, while CollPlant Biotechnologies is growing revenue faster (+360.4% vs -0.7%). CollPlant Biotechnologies converts more of its revenue into profit, with a net margin of -484.6% versus -211666.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HSCS-19.91%OPHI-32.54%
+2%-16%-34%
Nov 12, 20261 yearNov 20, 2026
HSCS-14.82%OPHI-14.25%
+1%-7%-16%
Nov 9, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HSCS versus OPHI key metrics
MetricHSCSOPHI
Share price$1.81$3.13
Market cap$10.42M$9.63M
1-day change-10.84%-2.49%
YTD return-41.42%—
1-year return-23.31%—
EPS (TTM)$-3.21$-9.33
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$4.32K$2.37M
Revenue growth (YoY)-0.71%+360.39%
Net income (latest FY)$-9.14M$-11.49M
Gross margin59.06%64.78%
Operating margin-194787.38%-484.31%
Net margin-211666.47%-484.56%
52-week high$5.25$22.50
52-week low$1.63$2.64
Distance from 52-week high-65.52%-86.09%
Analyst consensusbuy—
Avg. price target upside+562.98%—
Average volume162.54K385.37K
Shares outstanding5.76M3.08M
Employees14—
SectorHealth CareHealth Care
IndustryIndustrial SpecialtiesIndustrial Specialties

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CollPlant Biotechnologies is more profitable, keeping -484.6 cents of every revenue dollar as net income versus -211666.5 cents for HeartSciences.
  • CollPlant Biotechnologies grew revenue faster in its latest fiscal year (+360.39% vs -0.71%).

About HeartSciences

HSCS stock →

HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-native vendor- and device-agnostic ECG management platform.

Health Care · Industrial Specialties · 14 employees

HSCS vs OPHI FAQ

Which is bigger, HeartSciences or CollPlant Biotechnologies?

HeartSciences (HSCS) is larger, with a market capitalization of $10.42M compared with $9.63M for CollPlant Biotechnologies (OPHI).

Are HeartSciences and CollPlant Biotechnologies in the same industry?

Yes. Both are classified in the Industrial Specialties industry within the Health Care sector.

More comparisons